Advertisement

Annals of Hematology

, Volume 97, Issue 11, pp 2039–2046 | Cite as

Rabbit antithymocyte globulin dose does not affect response or survival as first-line therapy for acquired aplastic anemia: a multicenter retrospective study

  • Diego V. CléEmail author
  • Elias H. Atta
  • Danielle S. P. Dias
  • Carlos B. L. Lima
  • Mariana Bonduel
  • Gabriela Sciuccati
  • Larissa A. Medeiros
  • Michel M. de Oliveira
  • Patricia B. Blum Fonseca
  • Sara T. O. Saad
  • Nelson Hamerschlak
  • Marco A. Salvino
  • Marlene P. Garanito
  • Antonio Pazin-Filho
  • Phillip Scheinberg
  • Rodrigo T. Calado
Original Article

Abstract

In a prospective randomized study, treatment for aplastic anemia (AA) with rabbit antithymocyte globulin (r-ATG) and cyclosporine showed inferior hematological response and survival in comparison to horse antithymocyte globulin (h-ATG) and cyclosporine. However, h-ATG was discontinued in most Asian, South American, and European countries, where r-ATG became the only ATG formulation available. We retrospectively evaluated consecutive patients with acquired AA who received either rabbit (n = 170) or horse (n = 85) ATG and cyclosporine for first-line treatment from 1992 to 2014 in seven referral centers in Brazil and Argentina. Overall response at 3 months was 17% (95%CI, 11–23%) for r-ATG and 44% (95%CI, 33–55%) for h-ATG (p < 0.001). At 6 months, it was 31% (95%CI, 34–39%) for r-ATG and 59% (95%CI, 48–69%) for h-ATG (p < 0.001). Overall survival at 5 years was 57% (95%CI, 47–65%) for r-ATG and 80% (95%CI, 69–87%) for h-ATG (log-rank = 0.001). Relapse was significantly higher in patients receiving h-ATG (28%; 95%CI, 17–43%) as compared to r-ATG (9.4%; 95%CI, 4–21%; log-rank, p = 0.01). The type of ATG was the only factor associated with both response and survival. The r-ATG dose varied from 1 to 5 mg/kg/day, but it did not correlate with outcomes. In summary, this is the largest multicenter study comparing the two ATG formulations in AA. Our results indicate that the dose of r-ATG does not influence hematologic response or survival in first-line therapy for acquired AA. Considering the toxicity and costs of r-ATG, our findings challenge its aggregate benefit to cyclosporine therapy and further strengthen that h-ATG should remain standard therapy in AA.

Keywords

Aplastic anemia Antithymocyte globulin ATG dose Response Survival 

Notes

Authors’ contributions

DVC, EHA, DSPD, CBLL, MB, GS, LAM, MMO, PBBF, STOS, NH, MAS, and MPG collected patient data and participated in interim discussions. DVC, RTC, and APF performed the statistical analysis. DVC, RTC, and PS participated in study conceptualization, data analysis as well as interim discussions; oversaw the analysis; and wrote the paper. All authors approved the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interests.

Research involving human participants

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

The study was approved in 12/29/2014 by the ethics committee at the Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da USP, Ribeirão Preto, SP, Brazil, under the reference number 958.097.

Informed consent

Informed consent was obtained from all participants and was waived from those who lost follow-up and were not found.

References

  1. 1.
    Young NS, Calado RT, Scheinberg P (2006) Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 108:2509–2519CrossRefGoogle Scholar
  2. 2.
    Young NS, Scheinberg P, Calado RT (2008) Aplastic anemia. Curr Opin Hematol 15:162–168CrossRefGoogle Scholar
  3. 3.
    Townsley DM, Scheinberg P, Winkler T, Desmond R, Dumitriu B, Rios O, Weinstein B, Valdez J, Lotter J, Feng X, Desierto M, Leuva H, Bevans M, Wu C, Larochelle A, Calvo KR, Dunbar CE, Young NS (2017) Eltrombopag added to standard immunosuppression for aplastic Anemia. N Engl J Med 376:1540–1550CrossRefGoogle Scholar
  4. 4.
    Atta EH, Dias DS, Marra VL, de Azevedo AM (2010) Comparison between horse and rabbit antithymocyte globulin as first-line treatment for patients with severe aplastic anemia: a single-center retrospective study. Ann Hematol 89:851–859CrossRefGoogle Scholar
  5. 5.
    Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Biancotto A, Wu CO, Young NS (2011) Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med 365:430–438CrossRefGoogle Scholar
  6. 6.
    Scheinberg P, Fischer SH, Li L, Nunez O, Wu CO, Sloand EM, Cohen JI, Young NS, John Barrett A (2007) Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood 109:3219–3224CrossRefGoogle Scholar
  7. 7.
    Feng X, Kajigaya S, Solomou EE, Keyvanfar K, Xu X, Raghavachari N, Munson PJ, Herndon TM, Chen J, Young NS (2008) Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. Blood 111:3675–3683CrossRefGoogle Scholar
  8. 8.
    Lopez M, Clarkson MR, Albin M, Sayegh MH, Najafian N (2006) A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol 17:2844–2853CrossRefGoogle Scholar
  9. 9.
    Li X, Shi J, Ge M, Shao Y, Huang J, Huang Z, Zhang J, Nie N, Zheng Y (2013) Outcomes of optimized over standard protocol of rabbit antithymocyte globulin for severe aplastic anemia: a single-center experience. PLoS One 8:e56648CrossRefGoogle Scholar
  10. 10.
    Scheinberg P, Young NS (2012) How I treat acquired aplastic anemia. Blood 120:1185–1196CrossRefGoogle Scholar
  11. 11.
    Chuncharunee S, Wong R, Rojnuckarin P, Chang CS, Chang KM, Lu MY, Hwang WL, Koh LP, Chen TY, Leung AY et al (2016) Efficacy of rabbit antithymocyte globulin as first-line treatment of severe aplastic anemia: an Asian multicenter retrospective study. Int J Hematol 104:454–461CrossRefGoogle Scholar
  12. 12.
    Kaufman DW, Kelly JP, Levy M, Shapiro S (1991) The drug etiology of agranulocytosis and aplastic anemia. Oxford University Press, New YorkGoogle Scholar
  13. 13.
    Camitta BM, Rappeport JM, Parkman R, Nathan DG (1975) Selection of patients for bone marrow transplantation in severe aplastic anemia. Blood 45:355–363PubMedGoogle Scholar
  14. 14.
    Rosenfeld S, Follmann D, Nunez O, Young NS (2003) Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA 289:1130–1135CrossRefGoogle Scholar
  15. 15.
    Maschan A, Bogatcheva N, Kryjanovskii O, Shneider M, Litvinov D, Mitiushkina T, Timakov A, Timakova M, Samotchatova E, Rumiantsev A (1999) Results at a single Centre of immunosuppression with cyclosporine a in 66 children with aplastic anaemia. Br J Haematol 106:967–970CrossRefGoogle Scholar
  16. 16.
    Shetty M, Narendra AM, Adiraju KP, Modugu NR (2016) Study of aplastic Anaemia with cyclosporine in resource poor setting. J Clin Diagn Res 10:OC15–OC18PubMedPubMedCentralGoogle Scholar
  17. 17.
    Mahapatra M, Singh PK, Agarwal M, Prabhu M, Mishra P, Seth T, Tyagi S, Patil HP, Saxena R (2015) Epidemiology, Clinico-Haematological Profile and Management of Aplastic Anaemia: AIIMS experience. J Assoc Physicians India 63:30–35PubMedGoogle Scholar
  18. 18.
    Marsh JC, Bacigalupo A, Schrezenmeier H, Tichelli A, Risitano AM, Passweg JR, Killick SB, Warren AJ, Foukaneli T, Aljurf M, al-Zahrani HA, Höchsmann B, Schafhausen P, Roth A, Franzke A, Brummendorf TH, Dufour C, Oneto R, Sedgwick P, Barrois A, Kordasti S, Elebute MO, Mufti GJ, Socie G, European Blood and Marrow Transplant Group Severe Aplastic Anaemia Working Party (2012) Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT severe aplastic Anaemia working party. Blood 119:5391–5396CrossRefGoogle Scholar
  19. 19.
    Yoshimi A, Niemeyer CM, Fuhrer MM, Strahm B (2013) Comparison of the efficacy of rabbit and horse antithymocyte globulin for the treatment of severe aplastic anemia in children. Blood 121:860–861CrossRefGoogle Scholar
  20. 20.
    Jeong DC, Chung NG, Cho B, Zou Y, Ruan M, Takahashi Y, Muramatsu H, Ohara A, Kosaka Y, Yang W, Kim HK, Zhu X, Kojima S (2014) Long-term outcome after immunosuppressive therapy with horse or rabbit antithymocyte globulin and cyclosporine for severe aplastic anemia in children. Haematologica 99:664–671CrossRefGoogle Scholar
  21. 21.
    Afable MG 2nd, Shaik M, Sugimoto Y, Elson P, Clemente M, Makishima H, Sekeres MA, Lichtin A, Advani A, Kalaycio M et al (2011) Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia. Haematologica 96:1269–1275CrossRefGoogle Scholar
  22. 22.
    Shin SH, Yoon JH, Yahng SA, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Kim HJ, Cho SG, Kim DW, Min WS, Park CW, Lee JW (2013) The efficacy of rabbit antithymocyte globulin with cyclosporine in comparison to horse antithymocyte globulin as a first-line treatment in adult patients with severe aplastic anemia: a single-center retrospective study. Ann Hematol 92:817–824CrossRefGoogle Scholar
  23. 23.
    Vallejo C, Montesinos P, Polo M, Cuevas B, Morado M, Rosell A, Xicoy B, Diez JL, Salamero O, Cedillo A et al (2015) Rabbit antithymocyte globulin versus horse antithymocyte globulin for treatment of acquired aplastic anemia: a retrospective analysis. Ann Hematol 94:947–954CrossRefGoogle Scholar
  24. 24.
    Zheng Y, Liu Y, Chu Y (2006) Immunosuppressive therapy for acquired severe aplastic anemia (SAA): a prospective comparison of four different regimens. Exp Hematol 34:826–831CrossRefGoogle Scholar
  25. 25.
    Suzuki T, Kobayashi H, Kawasaki Y, Okazuka K, Hatano K, Fujiwara S, Oh I, Ohmine K, Kanda Y (2016) Efficacy of combination therapy with anti-thymocyte globulin and cyclosporine a as a first-line treatment in adult patients with aplastic anemia: a comparison of rabbit and horse formulations. Int J Hematol 104:446–453CrossRefGoogle Scholar
  26. 26.
    Brennan DC, Flavin K, Lowell JA, Howard TK, Shenoy S, Burgess S, Dolan S, Kano JM, Mahon M, Schnitzler MA, Woodward R, Irish W, Singer GG (1999) A randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 67:1011–1018CrossRefGoogle Scholar
  27. 27.
    Kekre N, Zhang Y, Zhang MJ, Carreras J, Ahmed P, Anderlini P, Atta EH, Ayas M, Boelens JJ, Bonfim C, Deeg HJ, Kapoor N, Lee JW, Nakamura R, Pulsipher MA, Eapen M, Antin JH (2017) Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia. Haematologica 102:1291–1298CrossRefGoogle Scholar
  28. 28.
    Atta EH, de Oliveira DC, Bouzas LF, Nucci M, Abdelhay E (2014) Less graft-versus-host disease after rabbit antithymocyte globulin conditioning in unrelated bone marrow transplantation for leukemia and myelodysplasia: comparison with matched related bone marrow transplantation. PLoS One 9:e107155CrossRefGoogle Scholar
  29. 29.
    Scheinberg P, Nunez O, Wu C, Young NS (2006) Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetil. Br J Haematol 133:606–611CrossRefGoogle Scholar
  30. 30.
    Scheinberg P, Wu CO, Nunez O, Scheinberg P, Boss C, Sloand EM, Young NS (2009) Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica 94:348–354CrossRefGoogle Scholar
  31. 31.
    Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Wu CO, Young NS (2012) Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia. Blood 119:345–354CrossRefGoogle Scholar
  32. 32.
    Flynn J, Cox CV, Rizzo S, Foukaneli T, Rice K, Murphy M, Welsh J, Rutherford TR, Gordon-Smith EC, Gibson FM (2003) Direct binding of antithymoctye globulin to haemopoietic progenitor cells in aplastic anaemia. Br J Haematol 122:289–297CrossRefGoogle Scholar
  33. 33.
    Huang AT, Mold NG, Zhang SF (1987) Antithymocyte globulin stimulates human hematopoietic progenitor cells. Proc Natl Acad Sci U S A 84:5942–5946CrossRefGoogle Scholar
  34. 34.
    Killick SB, Marsh JC, Gordon-Smith EC, Sorlin L, Gibson FM (2000) Effects of antithymocyte globulin on bone marrow CD34+ cells in aplastic anaemia and myelodysplasia. Br J Haematol 108:582–591CrossRefGoogle Scholar
  35. 35.
    Naparstek E, Delukina M, Or R, Nagler A, Kapelushnik J, Varadi G, Strauss N, Cividalli G, Aker M, Brautbar C, Waldmann H, Hale G, Slavin S (1999) Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies. Exp Hematol 27:1210–1218CrossRefGoogle Scholar
  36. 36.
    Socie G, Rosenfeld S, Frickhofen N, Gluckman E, Tichelli A (2000) Late clonal diseases of treated aplastic anemia. Semin Hematol 37:91–101CrossRefGoogle Scholar
  37. 37.
    Maciejewski JP, Risitano A, Sloand EM, Nunez O, Young NS (2002) Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood 99:3129–3135CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Diego V. Clé
    • 1
    Email author
  • Elias H. Atta
    • 2
    • 3
  • Danielle S. P. Dias
    • 2
  • Carlos B. L. Lima
    • 2
  • Mariana Bonduel
    • 4
  • Gabriela Sciuccati
    • 4
  • Larissa A. Medeiros
    • 5
  • Michel M. de Oliveira
    • 5
  • Patricia B. Blum Fonseca
    • 6
  • Sara T. O. Saad
    • 7
  • Nelson Hamerschlak
    • 8
  • Marco A. Salvino
    • 9
  • Marlene P. Garanito
    • 10
  • Antonio Pazin-Filho
    • 1
  • Phillip Scheinberg
    • 1
    • 11
  • Rodrigo T. Calado
    • 1
  1. 1.Department of Internal Medicine, Ribeirão Preto School of MedicineUniversity of São PauloRibeirão PretoBrazil
  2. 2.CEMO, Brazilian National Cancer InstituteRio de JaneiroBrazil
  3. 3.Haematopoietic Stem Cell ProgramRio de JaneiroBrazil
  4. 4.Servicio de Hematología-OncologíaHospital de Pediatría “Prof. Dr. Juan P. Garrahan”Buenos AiresArgentina
  5. 5.Bone Marrow Transplantation UnitFederal University of ParanáCuritibaBrazil
  6. 6.Darcy Vargas Children’s HospitalSão PauloBrazil
  7. 7.Hematology and Transfusion Medicine CenterHemocentro, University of CampinasCampinasBrazil
  8. 8.Hospital Israelita Albert EinsteinSão PauloBrazil
  9. 9.Bone Marrow Transplantation unitFederal University of BahiaSalvadorBrazil
  10. 10.Children’s InstituteUniversity of São Paulo School of MedicineSão PauloBrazil
  11. 11.Centro Oncológico do Hospital A Beneficência PortuguesaSão PauloBrazil

Personalised recommendations